^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CD276 expression

i
Other names: CD276, CD276 Molecule, CD276 Antigen, B7 Homolog 3, B7-H3, B7RP-2
Entrez ID:
Related biomarkers:
3d
Impact of B7-H3 expression on metastasis, immune exhaustion and JAK/STAT and PI3K/AKT pathways in clear cell renal cell carcinoma. (PubMed, Oncoimmunology)
Furthermore, knocking down B7-H3 expression in renal cancer cells by siRNA and CRISPR/Cas resulted in lower 2D and 3D cell proliferation and viability as well as increased sensitivity to TKI axitinib. Together, our findings suggest a pro-oncogenic and immune evasive role for B7-H3 in ccRCC and highlight B7-H3 as an actionable novel immune checkpoint protein in combination with TKI in advanced renal cancer.
Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
|
Inlyta (axitinib)
5d
Prognostic value of B7-H3 expression in metastatic renal cell carcinoma and its impact on immunotherapy response. (PubMed, BMC Cancer)
High B7-H3 expression is associated with poorer survival outcomes and reduced response to nivolumab in metastatic RCC patients. B7-H3 may serve as a predictive biomarker for immunotherapy response. Future studies should explore targeting B7-H3 in combination with existing therapies to enhance treatment efficacy.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
CD276 (CD276 Molecule)
|
CD276 expression
|
Opdivo (nivolumab)
15d
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity. (PubMed, J Immunother Cancer)
B7-H3 nanoCAR-T cells showed promise for glioblastoma therapy following in vitro characterization, but limiting in vivo toxicity was observed. Off-tumor recognition of healthy mouse tissue by the cross-reactive B7-H3 nanoCAR-T cells was identified as a potential cause for this toxicity, warranting caution when using highly sensitive nanoCAR-T cells, recognizing the low-level expression of B7-H3 on healthy tissue.
Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
15d
Development of B7-H3 targeted CAR-T cells for renal cell carcinoma therapy: in vitro and in vivo efficacy. (PubMed, Clin Transl Oncol)
The current study suggests that B7-H3 CAR-T cells exhibit significant efficacy in targeting and eliminating RCC cells, indicating a promising cellular immunotherapy approach for RCC treatment.
Preclinical • Journal • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • IL2 (Interleukin 2) • GZMB (Granzyme B)
|
CD276 expression
16d
Biomimetic Targeted Co-Delivery System Engineered from Genomic Insights for Precision Treatment of Osteosarcoma. (PubMed, Adv Sci (Weinh))
Furthermore, it is observed that this co-delivery system can activate immune microenvironment, increasing CD8+ T cell infiltration and converting osteosarcoma from an immune-cold to an immune-hot tumor. In summary, the co-delivery system is an effective therapeutic strategy and holds promise as a novel approach for osteosarcoma treatment.
Journal • PARP Biomarker
|
HRD (Homologous Recombination Deficiency) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule)
|
CDK4 amplification • CD276 expression
18d
Role of B7-H3 in predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. (PubMed, BJUI Compass)
This suggests B7-H3's potential as a predictive biomarker for chemotherapy response. Further research is needed to explore the role of B7-H3 on platinum-based chemotherapy response in urothelial cancer.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
25d
New P1 trial • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)
|
EGFR mutation • HER-2 negative • EGFR wild-type • CD276 expression
|
Tevimbra (tislelizumab-jsgr)
1m
B7-H3 is widely expressed in soft tissue sarcomas. (PubMed, BMC Cancer)
These data show high levels of B7-H3 positivity across soft tissue sarcoma subtypes, suggesting its feasibility as a therapeutic target for future sarcoma treatments. Future clinical trials are needed to evaluate whether targeting B7-H3 can provide clinical benefit to help patients with sarcoma.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule)
|
PD-L1 expression • CD276 expression
2ms
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
P1/2, N=25, Suspended, Dushu Lake Hospital Affiliated to Soochow University | Recruiting --> Suspended
Trial suspension
|
CD276 (CD276 Molecule)
|
CD276 expression
|
QH104
2ms
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma. (PubMed, Neuro Oncol)
Intraoperative iCer IPI + NIVO with postoperative iCav NIVO ± IPI up to biweekly doses of 1 mg IPI + 10 mg NIVO is feasible and safe, showing encouraging OS in rHGG patients. ClinicalTrials.gov registration: NCT03233152.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
PD-1 (Programmed cell death 1) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
|
CD276 expression
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
2ms
Journal • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD276 (CD276 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • CA 19-9 (Cancer antigen 19-9) • ITGB5 (Integrin Subunit Beta 5)
|
CD276 expression
2ms
Expression of B7-H3 and B7-H4 in Gastric Gastrointestinal Stromal Tumors. (PubMed, Appl Immunohistochem Mol Morphol)
The management of GIST was revolutionized by the introduction of imatinib, a KIT inhibitor, which has become the standard first-line treatment for metastatic GIST...B7-H3 is expressed at a particularly high rate in GISTs. This suggests that B7-H3 might operate as part of an immune checkpoint in GISTs.
Journal • Stroma
|
CD276 (CD276 Molecule) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
|
CD276 expression • VTCN1 underexpression
|
imatinib
2ms
B7H3 Immune Checkpoint Overexpression Is Associated with Decreased Complete Response Rates to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. (PubMed, Diagnostics (Basel))
Elevated B7H3 expression is associated with reduced oCR rates in LARC, highlighting its potential role as a prognostic biomarker. Further studies with larger cohorts are warranted to validate these findings and explore B7H3-targeted therapies as a treatment strategy for LARC.
Journal • Metastases
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
2ms
Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3. (PubMed, Mol Pharm)
Collectively, these results indicated that [89Zr]Zr-DFO-hu4G4 was successfully fabricated and applied in B7-H3-targeted tumor PET/CT imaging, which showed excellent imaging quality and tumor detection efficacy in tumor-bearing mice. It is a promising imaging agent for identifying tumors that overexpress B7-H3 for future clinical applications.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
2ms
CD276 as a promising diagnostic and prognostic biomarker for bladder cancer through bioinformatics and clinical research. (PubMed, Front Oncol)
CD276 is markedly upregulated in bladder cancer and associated with severe pathological features, advanced disease, potential for metastasis, and diminished survival rates. It may promote bladder cancer development and progression by influencing extracellular matrix-related-related pathways, making it a viable diagnostic and prognostic biomarker for bladder cancer.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression • CD2 overexpression
3ms
Radiomic features based on pyradiomics predict CD276 expression associated with breast cancer prognosis. (PubMed, Heliyon)
CD276 expression levels can have an impact on cancer prognosis. The MRI-based radiomic signature described in this study can discriminate the CD276 expression status.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
3ms
B7-H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion. (PubMed, Immun Inflamm Dis)
Our findings suggest that B7-H3 may accelerate tumor growth, tumor cell invasion, and EMT, and interact with 4-1BB to produce CD8+ T cell exhaustion that inhibits tumor immunity. B7-H3 might serve as a novel target for treating NPC.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD276 (CD276 Molecule) • TNFA (Tumor Necrosis Factor-Alpha)
|
CD276 expression • CD8 expression
7ms
The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas. (PubMed, Front Immunol)
Finally, CC-3 induced potent target cell lysis in a target cell restricted manner. Based on these results, a clinical trial evaluating CC-3 in soft tissue sarcoma is currently in preparation.
Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
|
CC-3
7ms
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target across Human Malignancies. (PubMed, Cancer Res Commun)
We have begun to define the genomic, transcriptomic, clinical, and immunological features associated with B7-H3 expression in 50 cancer types. We report novel clinical and molecular features of B7-H3-high tumors which may inform how current B7-H3 therapeutics should be deployed and prioritized.
Journal • Pan tumor
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD276 expression • TP53 expression
|
MI Tumor Seek™
8ms
B7-H3 Expression in Breast Cancer and Brain Metastasis. (PubMed, Int J Mol Sci)
However, not all brain metastases showed high levels of expression, with those from colorectal and renal tumours showing a low frequency of B7-H3 expression (0/14 and 2/16, respectively). The prevalence of B7-H3 expression in breast cancers and breast cancer brain metastases indicates potential opportunities for B7-H3 targeted therapies in breast cancer management.
Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
8ms
Comparison of approaches for increasing affinity of affibody molecules for imaging of B7-H3: dimerization and affinity maturation. (PubMed, EJNMMI Radiopharm Chem)
The improved functional affinity by dimerization does not compensate the disadvantage of increased molecular size for imaging purposes.
Journal
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
8ms
Pro-cancer role of CD276 as a novel biomarker for clear cell renal cell carcinoma. (PubMed, Urol Oncol)
CD276 expression was significantly increased in ccRCC tissues and cells and positively correlated with patient prognosis. CD276 is a potential prognostic biomarker of ccRCC. Overall, this study provides a potential therapeutic strategy for ccRCC.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
8ms
Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma. (PubMed, Front Immunol)
The iPS CD276-targeted CAR-NK cells, comparing with the iPS NK cells and the NK-free medium, exhibited specific and significant cytotoxic activity against CD276-positive ESCC PSO rather than CD276-negative NC PSO, and exhibited significant cytotoxicity against CD276-expressing cultured ESCC cells, as well as against CD276-expressing KYSE-150 in vitro and in BNDG mouse xenograft. The efficacy of the iPSC CD276-targeted CAR-NK cells demonstrated by their successful treatment of CD276-expressing ESCC in a multitude of pre-clinical models implied that they hold tremendous therapeutic potential for treating patients with CD276-expressing ESCC.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
8ms
A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation. (PubMed, J Exp Clin Cancer Res)
This study demonstrates a novel high-content and high-throughput screen can identify drugs to enhance CAR T cell activity. This and other high-content technologies will pave the way to develop clinical trials implementing rational drug plus CAR T cell combinatorial therapies. Importantly, the technique could also be repurposed for an array of basic and translational research applications where drugs are needed to modulate cell surface protein expression.
FDA event • Journal • CAR T-Cell Therapy
|
CD276 (CD276 Molecule) • PRKCA (Protein Kinase C Alpha)
|
CD19 positive • CD276 expression
|
B7-H3 CAR-T
8ms
CD276-dependent efferocytosis by tumor-associated macrophages promotes immune evasion in bladder cancer. (PubMed, Nat Commun)
Proving the principle, we show that simultaneous blockade of CD276 and PD-1 restrain tumor growth better than any of the components as a single intervention. Taken together, our study supports a role for CD276 in efferocytosis by TAMs, which is potentially targetable for combination immune therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase) • CD276 (CD276 Molecule) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD4 (CD4 Molecule)
|
MERTK expression • CD276 expression
8ms
B7-H3 suppresses CD8+ T cell immunologic function through reprogramming glycolytic metabolism. (PubMed, J Cancer)
Mechanistically, our study suggests B7-H3's influence on metabolism might be mediated through the phosphoinositide3-kinase (PI3K)/ protein kinase B (Akt)/ mammalian target of rapamycin (mTOR) signaling pathway. This research unveils how B7-H3 affects immune functions via metabolic reprogramming.
Journal
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD276 (CD276 Molecule)
|
CD276 expression
8ms
Small extracellular vesicle piR-hsa-30937 derived from pancreatic neuroendocrine neoplasms upregulates CD276 in macrophages to promote immune evasion. (PubMed, Cancer Immunol Res)
Thus, our data show that PNEN-derived sEV piR-hsa-30937 promotes CD276 expression in macrophages through the PTEN/AKT pathway and that CD276+ TAMs suppress T-cell antitumor immunity. sEV piR-hsa-30937 and CD276 are potential therapeutic targets for immunotherapy of PNEN.
Journal • IO biomarker
|
CD276 (CD276 Molecule) • CD68 (CD68 Molecule)
|
CD276 expression
8ms
Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity. (PubMed, Cancer Immunol Immunother)
In canine OS xenograft models, little anti-tumor activity was generated by B7-H3 CAR T cells; whereas, B7-H3-CXCR2 CAR T cells significantly inhibited tumor growth, inducing complete tumor elimination in most treated mice. These findings indicated therefore that addition of a chemokine receptor could significantly improve the anti-tumor activity of canine B7-H3 CAR T cells, and that evaluation of this new dual CAR construct in dogs with primary or metastatic OS is warranted since such studies could provide a critical and realistic validation of the chemokine receptor concept.
Journal • CAR T-Cell Therapy • IO biomarker
|
CD276 (CD276 Molecule) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
|
CD276 expression
9ms
B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma. (PubMed, Pathol Res Pract)
With clinical translational value, the predictive value of B7-H3 for conventional immunotherapy was detected using the Kaplan-Meier plotter tool, and the results showed that melanoma patients with high B7-H3 expression were insensitive to anti-PD-1 and anti-CTLA-4 immunotherapy. In conclusion, we first investigate the expression of B7-H3 in melanoma and its correlations with the TME features, and indicate B7-H3 as a promising therapeutic target in melanoma patients that are insensitive to conventional immunotherapy.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
|
CD276 (CD276 Molecule)
|
CD276 overexpression • CD276 expression
9ms
Clinicopathological features and prognostic value of CD276 expression in female reproductive system malignancies: A meta-analysis. (PubMed, Taiwan J Obstet Gynecol)
In terms of prognosis: CD276 expression is strongly associated with shorter OS in patients with female reproductive system malignancies [HR = 3.33, 95 % CI = 1.36-8.15, P = 0.01]. CD276 may be a new target for immunotherapy and a biomarker for predicting poor prognosis of female reproductive system malignancies.
Retrospective data • Review • Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
9ms
Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis. (PubMed, BMC Urol)
Our meta-analysis unveils the complex role of B7-H3 in bladder cancer progression. It appears to be directly involved in tumor infiltration and recurrence but cannot definitively serve as a prognostic biomarker for bladder cancer. To validate these findings, further well-designed studies, encompassing larger sample sizes and diverse racial backgrounds, are warranted.
Retrospective data • Review • Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
9ms
Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2023 --> Jun 2024
Trial completion date • IO biomarker
|
AR (Androgen receptor) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
CD276 expression • LAG3 expression • HAVCR2 expression • LAMP1 expression
|
enoblituzumab (MGA271)
9ms
Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3). (PubMed, Front Oncol)
Clinical trial results will be published in peer-reviewed journals. Trial registration numbers: ClinicalTrials.cov Registry (NCT05999396) and EU ClinicalTrials Registry (EU trial number 2022-503084-15-00).
P1 data • Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
|
CC-3
9ms
PathoGraph: An Attention-Based Graph Neural Network Capable of Prognostication Based on CD276 Labelling of Malignant Glioma Cells. (PubMed, Cancers (Basel))
The graphs permit predicting individual patient survival on the basis of GSC community features. Our experiments lay a foundation for the use of the BCNN-abGCN tool chain in automated diagnostic prognostication using immunohistochemically labelled histological slides, but the method is essentially generic and potentially a widely usable tool in medical research and AI based healthcare applications.
Journal
|
CD276 (CD276 Molecule)
|
CD276 expression
10ms
CD276 promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma through the TGF-β/SMAD signaling. (PubMed, Clin Exp Metastasis)
CD276 is significant upregulation in ESCC tissues and facilitates the EMT process in ESCC cells via the TGF-β/SMAD signaling, thus promoting the progression of ESCC.
Journal
|
CD276 (CD276 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
|
CD276 overexpression • CD276 expression • CD2 overexpression
10ms
Dual Inhibition of B7-H3 and EGFR Overcomes Acquired Chemoresistance in Colon Adenocarcinoma. (PubMed, J Cancer)
B7-H3 may stabilize EGFR to activate its downstream pathway for cancer cell proliferation and resistance to oxaliplatin (OXP)...Overall, these results showed that B7-H3 exhibited a high prevalence in COAD patients and was significantly associated with worse prognosis in COAD patients. Dual targeting of B7-H3 and EGFR signaling might be a potential therapeutic strategy for high-risk COAD patients.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
CD276 expression
|
oxaliplatin
10ms
Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. (PubMed, Cancer Lett)
Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.
Journal
|
CD8 (cluster of differentiation 8) • CD276 (CD276 Molecule) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • RELA (RELA Proto-Oncogene)
|
CD276 expression • CD8 expression
10ms
A promising target for breast cancer: B7-H3. (PubMed, BMC Cancer)
Thus, an innovative target for immunotherapy against BC may be the B7-H3 checkpoint.In this review, we discuss the structure and regulation of B7-H3 and its double costimulatory/coinhibitory function within the framework of cancer and normal physiology. Then we expound the malignant behavior of B7-H3 in BC and its role in the tumor microenvironment (TME) and finally focus on targeted drugs against B7-H3 that have opened new therapeutic opportunities in BC.
Review • Journal • IO biomarker
|
CD276 (CD276 Molecule)
|
CD276 expression
10ms
N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer. (PubMed, iScience)
Furthermore, rescue experiments demonstrated that reintroduction of B7-H3 considerably abolished the inhibitory effects on cell proliferation and invasion induced by silencing YTHDF1. Our results suggest that the YTHDF1-m6A-B7-H3 axis is crucial for CRC development and progression and may represent a potential therapeutic target for CRC treatment.
Journal
|
CD276 (CD276 Molecule) • YTHDF1 (YTH N6-Methyladenosine RNA Binding Protein 1)
|
CD276 expression
10ms
High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. (PubMed, NPJ Breast Cancer)
In addition, patients with B7-H3 high and PD-L1 low expression showed the lowest anti-tumor immune infiltration, the highest collagen level, and the lowest therapeutic responses to multiple therapies, which mostly belong to armored-cold tumors. Overall, this research provides a novel subtyping strategy based on the combination of B7-H3/PD-L1 expression, which leads to a novel approach for the management of TNBC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD276 (CD276 Molecule)
|
PD-L1 expression • PD-L1 underexpression • CD276 expression • PD-L1-L
11ms
High expression of B7-H3 on monocyte/macrophages in tumor microenvironment promotes lung cancer progression by inhibiting apoptosis. (PubMed, Transl Oncol)
Mechanistically, B7-H3 enhanced the antiapoptotic ability of macrophage by up-regulating HIF-1ɑ via activating NF-κB. Taken together, these results imply that B7-H3 as a therapeutic target could hold promise for enhancing anti-tumor immune responses in individuals diagnosed with lung cancer.
Journal
|
CD276 (CD276 Molecule) • MIR29A (MicroRNA 29a)
|
CD276 expression
11ms
Establishment of a pathomic-based machine learning model to predict CD276 (B7-H3) expression in colon cancer. (PubMed, Front Oncol)
We constructed a pathomics-based machine learning model for CD276 prediction directly from H&E-stained images in COAD. Through integrated analysis of the pathomic model and transcriptomics, the interpretability of the pathomic model provide a theoretical basis for further hypothesis and experimental research.
Journal • Machine learning
|
CD276 (CD276 Molecule)
|
CD276 expression